Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annual Congress

Rhea-AI Summary

Cogent Biosciences (Nasdaq: COGT) has announced a poster presentation at the European Hematology Association (EHA) Congress, scheduled for June 9-12, 2022. This presentation will highlight the initial results from the ongoing Phase 2 APEX trial assessing the efficacy of bezuclastinib in treating patients with advanced systemic mastocytosis (AdvSM). The abstract is accessible on the EHA website, with the poster set to be published on June 10, 2022. Bezuclastinib is aimed at inhibiting the KIT D816V mutation, a significant contributor to systemic mastocytosis.

Positive

• Presentation of initial clinical data from the Phase 2 APEX trial indicates progress in research.
• Bezuclastinib targets the KIT D816V mutation, a critical driver of systemic mastocytosis.

Negative

• None.

Poster to highlight initial data from on-going Phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM)

CAMBRIDGE, Mass. and BOULDER, Colo., May 12, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced a poster presentation at the European Hematology Association (EHA) Congress being held June 9-12, 2022. The poster will review initial clinical data from the Company’s ongoing Phase 2 APEX trial with bezuclastinib. The abstract is available on the EHA website at www.ehaweb.org and the poster will be published on the EHA Congress platform on June 10, 2022.

Presentation Title: A Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V inhibitor, in Adults with Advanced Systemic Mastocytosis (Apex): Methods, Baseline Data, and Early Insights
Session Type: Poster Session
Session Date and Time: Friday, June 10, 2022 - 16:30 - 17:45 CEST (10:30am-11:45am ET)
Abstract Number: P1049

About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting FGFR2 and ErbB2. Cogent Biosciences is based in Cambridge, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: Twitter and LinkedIn. Information that may be important to investors will be routinely posted on our website and Twitter.

Contact:
Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com

FAQ

What is the Phase 2 APEX trial about for COGT?

The Phase 2 APEX trial evaluates the efficacy of bezuclastinib in patients with advanced systemic mastocytosis.

When is the EHA Congress where COGT will present its data?

The EHA Congress is scheduled from June 9-12, 2022.

What mutation does bezuclastinib target?

Bezuclastinib targets the KIT D816V mutation, which is associated with systemic mastocytosis.

Where can I find the abstract for COGT's presentation?

The abstract is available on the EHA website.

What date will the poster be published during the EHA Congress?

The poster will be published on June 10, 2022.